COVID-19 Impact on Global Neurologic Disorders Therapeutics Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Neurologic Disorders Therapeutics Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Neurologic Disorders Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Central Nervous System (CNS)
  • 1.4.3 Peripheral Nervous System (PNS)
• 1.5 Market by Application
  • 1.5.1 Global Neurologic Disorders Therapeutics Market Share by Application: 2020 VS 2026
  • 1.5.2 Paralysis
  • 1.5.3 Muscle Weakness
  • 1.5.4 Poor Coordination
  • 1.5.5 Loss of Sensation
  • 1.5.6 Seizures
  • 1.5.7 Confusion
  • 1.5.8 Pain and Altered Levels of Consciousness
• 1.6 Coronavirus Disease 2019 (Covid-19): Neurologic Disorders Therapeutics Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Neurologic Disorders Therapeutics Industry
    • 1.6.1.1 Neurologic Disorders Therapeutics Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Neurologic Disorders Therapeutics Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Neurologic Disorders Therapeutics Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Neurologic Disorders Therapeutics Market Perspective (2015-2026)
• 2.2 Neurologic Disorders Therapeutics Growth Trends by Regions
  • 2.2.1 Neurologic Disorders Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Neurologic Disorders Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Neurologic Disorders Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Neurologic Disorders Therapeutics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Neurologic Disorders Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Neurologic Disorders Therapeutics Players by Market Size
  • 3.1.1 Global Top Neurologic Disorders Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Neurologic Disorders Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Neurologic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Neurologic Disorders Therapeutics Market Concentration Ratio
  • 3.2.1 Global Neurologic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Neurologic Disorders Therapeutics Revenue in 2019
• 3.3 Neurologic Disorders Therapeutics Key Players Head office and Area Served
• 3.4 Key Players Neurologic Disorders Therapeutics Product Solution and Service
• 3.5 Date of Enter into Neurologic Disorders Therapeutics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Neurologic Disorders Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Neurologic Disorders Therapeutics Forecasted Market Size by Type (2021-2026)

5 Neurologic Disorders Therapeutics Breakdown Data by Application (2015-2026)

• 5.1 Global Neurologic Disorders Therapeutics Market Size by Application (2015-2020)
• 5.2 Global Neurologic Disorders Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Neurologic Disorders Therapeutics Market Size (2015-2020)
• 6.2 Neurologic Disorders Therapeutics Key Players in North America (2019-2020)
• 6.3 North America Neurologic Disorders Therapeutics Market Size by Type (2015-2020)
• 6.4 North America Neurologic Disorders Therapeutics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Neurologic Disorders Therapeutics Market Size (2015-2020)
• 7.2 Neurologic Disorders Therapeutics Key Players in Europe (2019-2020)
• 7.3 Europe Neurologic Disorders Therapeutics Market Size by Type (2015-2020)
• 7.4 Europe Neurologic Disorders Therapeutics Market Size by Application (2015-2020)

8 China

• 8.1 China Neurologic Disorders Therapeutics Market Size (2015-2020)
• 8.2 Neurologic Disorders Therapeutics Key Players in China (2019-2020)
• 8.3 China Neurologic Disorders Therapeutics Market Size by Type (2015-2020)
• 8.4 China Neurologic Disorders Therapeutics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Neurologic Disorders Therapeutics Market Size (2015-2020)
• 9.2 Neurologic Disorders Therapeutics Key Players in Japan (2019-2020)
• 9.3 Japan Neurologic Disorders Therapeutics Market Size by Type (2015-2020)
• 9.4 Japan Neurologic Disorders Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Neurologic Disorders Therapeutics Market Size (2015-2020)
• 10.2 Neurologic Disorders Therapeutics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Neurologic Disorders Therapeutics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Neurologic Disorders Therapeutics Market Size by Application (2015-2020)

11 India

• 11.1 India Neurologic Disorders Therapeutics Market Size (2015-2020)
• 11.2 Neurologic Disorders Therapeutics Key Players in India (2019-2020)
• 11.3 India Neurologic Disorders Therapeutics Market Size by Type (2015-2020)
• 11.4 India Neurologic Disorders Therapeutics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Neurologic Disorders Therapeutics Market Size (2015-2020)
• 12.2 Neurologic Disorders Therapeutics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Neurologic Disorders Therapeutics Market Size by Type (2015-2020)
• 12.4 Central & South America Neurologic Disorders Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Biogen Inc.
  • 13.1.1 Biogen Inc. Company Details
  • 13.1.2 Biogen Inc. Business Overview and Its Total Revenue
  • 13.1.3 Biogen Inc. Neurologic Disorders Therapeutics Introduction
  • 13.1.4 Biogen Inc. Revenue in Neurologic Disorders Therapeutics Business (2015-2020))
  • 13.1.5 Biogen Inc. Recent Development
• 13.2 F. Hoffmann-La Roche Ltd.
  • 13.2.1 F. Hoffmann-La Roche Ltd. Company Details
  • 13.2.2 F. Hoffmann-La Roche Ltd. Business Overview and Its Total Revenue
  • 13.2.3 F. Hoffmann-La Roche Ltd. Neurologic Disorders Therapeutics Introduction
  • 13.2.4 F. Hoffmann-La Roche Ltd. Revenue in Neurologic Disorders Therapeutics Business (2015-2020)
  • 13.2.5 F. Hoffmann-La Roche Ltd. Recent Development
• 13.3 Johnson & Johnson Services Inc.
  • 13.3.1 Johnson & Johnson Services Inc. Company Details
  • 13.3.2 Johnson & Johnson Services Inc. Business Overview and Its Total Revenue
  • 13.3.3 Johnson & Johnson Services Inc. Neurologic Disorders Therapeutics Introduction
  • 13.3.4 Johnson & Johnson Services Inc. Revenue in Neurologic Disorders Therapeutics Business (2015-2020)
  • 13.3.5 Johnson & Johnson Services Inc. Recent Development
• 13.4 Novartis AG
  • 13.4.1 Novartis AG Company Details
  • 13.4.2 Novartis AG Business Overview and Its Total Revenue
  • 13.4.3 Novartis AG Neurologic Disorders Therapeutics Introduction
  • 13.4.4 Novartis AG Revenue in Neurologic Disorders Therapeutics Business (2015-2020)
  • 13.4.5 Novartis AG Recent Development
• 13.5 Pfizer Inc.
  • 13.5.1 Pfizer Inc. Company Details
  • 13.5.2 Pfizer Inc. Business Overview and Its Total Revenue
  • 13.5.3 Pfizer Inc. Neurologic Disorders Therapeutics Introduction
  • 13.5.4 Pfizer Inc. Revenue in Neurologic Disorders Therapeutics Business (2015-2020)
  • 13.5.5 Pfizer Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer